HIV status alters disease severity and immune cell responses in beta variant SARS-CoV-2 infection wave

  1. Farina Karim
  2. Inbal Gazy
  3. Sandile Cele
  4. Yenzekile Zungu
  5. Robert Krause
  6. Mallory Bernstein
  7. Khadija Khan
  8. Yashica Ganga
  9. Hylton Errol Rodel
  10. Ntombifuthi Mthabela
  11. Matilda Mazibuko
  12. Daniel Muema
  13. Dirhona Ramjit
  14. Thumbi Ndung'u
  15. Willem Hanekom
  16. Bernadett Gosnell
  17. Richard J Lessells
  18. Emily B Wong
  19. Tulio de Oliveira
  20. Yunus Moosa
  21. Gil Lustig
  22. Alasdair Leslie  Is a corresponding author
  23. Henrik Kløverpris  Is a corresponding author
  24. Alex Sigal  Is a corresponding author
  1. Africa Health Research Institute, South Africa
  2. University of KwaZulu-Natal, South Africa
  3. Africa Health Research Institute; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, South Africa
  4. Africa Health Research Institute; Division of Infection and Immunity, University College London, South Africa
  5. Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, South Africa
  6. KwaZulu-Natal Research Institute for TB-HIV, South Africa
  7. University of KwaZulu-Natal,SA, South Africa
  8. Centre for the AIDS Programme of Research in South Africa, South Africa
  9. African Health Research Institute, South Africa
  10. Africa Health Research Institute, University of KwaZulu-Natal, South Africa

Abstract

There are conflicting reports on the effects of HIV on COVID-19. Here we analyzed disease severity and immune cell changes during and after SARS-CoV-2 infection in 236 participants from South Africa, of which 39% were people living with HIV (PLWH), during the first and second (beta dominated) infection waves. The second wave had more PLWH requiring supplemental oxygen relative to HIV negative participants. Higher disease severity was associated with low CD4 T cell counts and higher neutrophil to lymphocyte ratios (NLR). Yet, CD4 counts recovered and NLR stabilized after SARS-CoV-2 clearance in wave 2 infected PLWH, arguing for an interaction between SARS-CoV-2 and HIV infection leading to low CD4 and high NLR. The first infection wave, where severity in HIV negative and PLWH was similar, still showed some HIV modulation of SARS-CoV-2 immune responses. Therefore, HIV infection can synergize with the SARS-CoV-2 variant to change COVID-19 outcomes.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files

Article and author information

Author details

  1. Farina Karim

    Division of Clinical Studies, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  2. Inbal Gazy

    University of KwaZulu-Natal, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  3. Sandile Cele

    Systems Infection Biology, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  4. Yenzekile Zungu

    Africa Health Research Institute, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  5. Robert Krause

    Africa Health Research Institute, Africa Health Research Institute; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  6. Mallory Bernstein

    Africa Health Research Institute, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  7. Khadija Khan

    Division of Clinical Studies, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  8. Yashica Ganga

    Africa Health Research Institute, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  9. Hylton Errol Rodel

    Systems Infection Biology, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  10. Ntombifuthi Mthabela

    Africa Health Research Institute, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  11. Matilda Mazibuko

    Africa Health Research Institute, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  12. Daniel Muema

    Africa Health Research Institute; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Africa Health Research Institute; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  13. Dirhona Ramjit

    Africa Health Research Institute, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  14. Thumbi Ndung'u

    Africa Health Research Institute, Africa Health Research Institute, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2962-3992
  15. Willem Hanekom

    Africa Health Research Institute; Division of Infection and Immunity, University College London, Africa Health Research Institute; Division of Infection and Immunity, University College London, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  16. Bernadett Gosnell

    Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durbans, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  17. Richard J Lessells

    University of KwaZulu-Natal, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0926-710X
  18. Emily B Wong

    KwaZulu-Natal Research Institute for TB-HIV, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  19. Tulio de Oliveira

    School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal,SA, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  20. Yunus Moosa

    Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  21. Gil Lustig

    Centre for the AIDS Programme of Research in South Africa, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  22. Alasdair Leslie

    African Health Research Institute, Durban, South Africa
    For correspondence
    Al.Leslie@ahri.org
    Competing interests
    The authors declare that no competing interests exist.
  23. Henrik Kløverpris

    Africa Health Research Institute, Africa Health Research Institute, Durban, South Africa
    For correspondence
    Henrik.Kloverpris@ahri.org
    Competing interests
    The authors declare that no competing interests exist.
  24. Alex Sigal

    School of Laboratory Medicine and Medical Sciences, Africa Health Research Institute, University of KwaZulu-Natal, Durban, South Africa
    For correspondence
    alex.sigal@ahri.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8571-2004

Funding

Bill and Melinda Gates Foundation (INV-018944)

  • Alex Sigal

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study protocol was approved by the University of KwaZulu-Natal Institutional Review Board (approval BREC/00001275/2020). Adult patients ($>$18 years old) presenting either at King Edward VIII or Clairwood Hospitals in Durban, South Africa, between 8 June to 25 September 2020, diagnosed to be SARS-CoV-2 positive as part of their clinical workup and able to provide informed consent were eligible for the study. Written informed consent was obtained for all enrolled participants.

Copyright

© 2021, Karim et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,369
    views
  • 250
    downloads
  • 31
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Farina Karim
  2. Inbal Gazy
  3. Sandile Cele
  4. Yenzekile Zungu
  5. Robert Krause
  6. Mallory Bernstein
  7. Khadija Khan
  8. Yashica Ganga
  9. Hylton Errol Rodel
  10. Ntombifuthi Mthabela
  11. Matilda Mazibuko
  12. Daniel Muema
  13. Dirhona Ramjit
  14. Thumbi Ndung'u
  15. Willem Hanekom
  16. Bernadett Gosnell
  17. Richard J Lessells
  18. Emily B Wong
  19. Tulio de Oliveira
  20. Yunus Moosa
  21. Gil Lustig
  22. Alasdair Leslie
  23. Henrik Kløverpris
  24. Alex Sigal
(2021)
HIV status alters disease severity and immune cell responses in beta variant SARS-CoV-2 infection wave
eLife 10:e67397.
https://doi.org/10.7554/eLife.67397

Share this article

https://doi.org/10.7554/eLife.67397

Further reading

    1. Microbiology and Infectious Disease
    Han Kang Tee, Simon Crouzet ... Caroline Tapparel
    Research Article Updated

    Because of high mutation rates, viruses constantly adapt to new environments. When propagated in cell lines, certain viruses acquire positively charged amino acids on their surface proteins, enabling them to utilize negatively charged heparan sulfate (HS) as an attachment receptor. In this study, we used enterovirus A71 (EV-A71) as the model and demonstrated that, unlike the parental MP4 variant, the cell-adapted strong HS-binder MP4-97R/167 G does not require acidification for uncoating and releases its genome in the neutral or weakly acidic environment of early endosomes. We experimentally confirmed that this pH-independent entry is not associated with the use of HS as an attachment receptor but rather with compromised capsid stability. We then extended these findings to another HS-dependent strain. In summary, our data indicate that the acquisition of capsid mutations conferring affinity for HS comes together with decreased capsid stability and allows EV-A71 to enter the cell via a pH-independent pathway. This pH-independent entry mechanism boosts viral replication in cell lines but may prove deleterious in vivo, especially for enteric viruses crossing the acidic gastric environment before reaching their primary replication site, the intestine. Our study thus provides new insight into the mechanisms underlying the in vivo attenuation of HS-binding EV-A71 strains. Not only are these viruses hindered in tissues rich in HS due to viral trapping, as generally accepted, but our research reveals that their diminished capsid stability further contributes to attenuation in vivo. This underscores the complex relationship between HS-binding, capsid stability, and viral fitness, where increased replication in cell lines coincides with attenuation in harsh in vivo environments like the gastrointestinal tract.

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease
    Louna Fruchard, Anamaria Babosan ... Zeynep Baharoglu
    Research Article

    Tgt is the enzyme modifying the guanine (G) in tRNAs with GUN anticodon to queuosine (Q). tgt is required for optimal growth of Vibrio cholerae in the presence of sub-lethal aminoglycoside concentrations. We further explored here the role of the Q34 in the efficiency of codon decoding upon tobramycin exposure. We characterized its impact on the overall bacterial proteome, and elucidated the molecular mechanisms underlying the effects of Q34 modification in antibiotic translational stress response. Using molecular reporters, we showed that Q34 impacts the efficiency of decoding at tyrosine TAT and TAC codons. Proteomics analyses revealed that the anti-SoxR factor RsxA is better translated in the absence of tgt. RsxA displays a codon bias toward tyrosine TAT and overabundance of RsxA leads to decreased expression of genes belonging to SoxR oxidative stress regulon. We also identified conditions that regulate tgt expression. We propose that regulation of Q34 modification in response to environmental cues leads to translational reprogramming of transcripts bearing a biased tyrosine codon usage. In silico analysis further identified candidate genes which could be subject to such translational regulation, among which DNA repair factors. Such transcripts, fitting the definition of modification tunable transcripts, are central in the bacterial response to antibiotics.